Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Metastatic Colorectal Cancer
95%
Circulating Tumor DNA
80%
Overall Survival
62%
Chemotherapy
61%
Biological Marker
56%
Progression Free Survival
46%
Colorectal Carcinoma
32%
Ovary Cancer
31%
Malignant Neoplasm
29%
Metastasis
26%
Bevacizumab
26%
Epidermal Growth Factor Receptor
23%
Phase II Trials
23%
Irinotecan
23%
Disease
20%
Ovary Carcinoma
20%
Rectum Cancer
17%
Lung Cancer
14%
Capecitabine
13%
Epidermal Growth Factor
13%
Non Small Cell Lung Cancer
12%
Vasculotropin
11%
Alpha Tocotrienol
11%
Breast Cancer
11%
Biliary Tract Cancer
11%
Chemoradiation Therapy
11%
Gemcitabine
11%
microRNA
11%
Colon Carcinoma
11%
Neuropeptide Y
10%
Interleukin 6
10%
Solid Malignant Neoplasm
10%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
9%
Receptor
9%
Vasculotropin A
9%
Recurrent Disease
9%
Oxaliplatin
8%
Tumor Marker
8%
Cetuximab
8%
Combination Therapy
8%
Monotherapy
7%
Adverse Event
7%
Ovary Tumor
7%
Carboplatin
7%
SARS Coronavirus
5%
Regorafenib
5%
DNA A
5%
Postcholecystectomy Syndrome
5%
Immunoglobulin
5%
Biochemistry, Genetics and Molecular Biology
Circulating Tumor DNA
77%
Blood Plasma
66%
Overall Survival
43%
Methylation
41%
Single-Nucleotide Polymorphism
40%
HOXA9
36%
KRAS
32%
Progression Free Survival
30%
MicroRNA
29%
Homeobox
23%
Real-Time Polymerase Chain Reaction
21%
Droplet Digital Polymerase Chain Reaction
21%
Vascular Endothelial Growth Factor A
20%
DNA Methylation
20%
Genotyping
18%
Vascular Endothelial Growth Factor
17%
Bevacizumab
17%
Wild Type
14%
Capecitabine
13%
Dynamics
12%
Colon
12%
Growth Factor-Like Domain
11%
Natural Killer Cell
11%
Epidermal Growth Factor
11%
Gemcitabine
11%
Poly ADP Ribose Polymerase
11%
Allele
11%
Multivariate Analysis
10%
Cell Activity
10%
Embase
10%
Clinical Trial
8%
Epidermal Growth Factor Receptor
8%
Medline
8%
Phase II Trials
8%
Kinase Insert Domain Receptor
7%
Gene Polymorphism
7%
TaqMan
7%
Computer Assisted Tomography
7%
Web of Science
7%
Cochrane Library
7%
Liquid
6%
Quantitative Technique
6%
Mir-126
6%
Copurification
6%
Tumor Marker
5%
Exon
5%
Intracellular Signaling
5%
Patient Coding
5%
DnaA
5%
Comorbidity
5%
Medicine and Dentistry
Cell-Free DNA
42%
Colorectal Carcinoma
35%
Circulating Tumor DNA
34%
Specific Tumor
27%
Neoplasm
26%
Biological Marker
25%
Ovarian Cancer
23%
Rectum Cancer
20%
Metastatic Colorectal Cancer
19%
Methylation
18%
Malignant Neoplasm
18%
Lung Cancer
17%
Meta-Analysis
17%
Systematic Review
17%
Chemoradiotherapy
17%
Progression Free Survival
17%
Overall Survival
16%
Chemotherapy
14%
DNA Methylation
12%
Diagnosis
12%
Gemcitabine
11%
Capecitabine
11%
Biliary Tract Cancer
11%
Bevacizumab
11%
Breast Cancer
11%
Homeobox
11%
Disease
11%
Krukenberg Tumor
10%
Metastatic Carcinoma
9%
Receptor
9%
Gene Expression
9%
Droplet Digital Polymerase Chain Reaction
9%
Hazard Ratio
9%
Phase II Trials
8%
Real-Time Polymerase Chain Reaction
8%
Lung Metastasis
8%
Treatment Response
7%
Irinotecan
7%
Ovarian Tumor
7%
microRNA 21
7%
Reproducibility
6%
High Risk Population
6%
Arm
6%
Multivariate Analysis
5%
Antisense
5%
Erlotinib
5%
Alpha Tocotrienol
5%
Epidermal Growth Factor Receptor
5%
DNA A
5%
Adjuvant Therapy
5%
